Autoantibodies to RNA helicase A: A new serologic marker of early lupus
| Autor: | Liza Hernandez, Sonali Narain, Yoshioki Yamasaki, Paulette Hahn, Hideo Yoshida, Hanno B. Richards, Westley H. Reeves, Mark S. Segal, Eric S. Sobel, Tolga Barker, Minoru Satoh, Edward K. L. Chan |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Aging medicine.medical_specialty Time Factors Immunology medicine.disease_cause Autoantigens Gene Expression Regulation Enzymologic White People snRNP Core Proteins Autoimmunity DEAD-box RNA Helicases Rheumatology Rheumatic Diseases Internal medicine medicine Humans Lupus Erythematosus Systemic Immunology and Allergy Pharmacology (medical) Aged Autoantibodies Systemic lupus erythematosus Lupus erythematosus Asian SnRNP Core Proteins business.industry Age Factors Autoantibody Hispanic or Latino Middle Aged Dermatomyositis Ribonucleoproteins Small Nuclear medicine.disease Neoplasm Proteins Black or African American Case-Control Studies Rheumatoid arthritis Indians North American business Anti-SSA/Ro autoantibodies |
| Zdroj: | Arthritis & Rheumatism. 56:596-604 |
| ISSN: | 1529-0131 0004-3591 |
| DOI: | 10.1002/art.22329 |
| Popis: | Objective To investigate the clinical and immunologic significance of autoantibodies to RNA helicase A (RHA) in patients with systemic rheumatic diseases. Methods The study group comprised 1,119 individuals enrolled in the University of Florida Center for Autoimmune Diseases registry from 2000 to 2005. Diagnoses were based on standard criteria. Autoantibodies were analyzed by immunoprecipitation and Western blot assays. Results Anti-RHA was observed in 17 (6.2%) of 276 patients with systemic lupus erythematosus (SLE), 2 patients with antiphospholipid antibodies, and 3 other patients, but anti-RHA was not observed in any patient with polymyositis/dermatomyositis, systemic sclerosis, rheumatoid arthritis, or Sjogren's syndrome. Anti-RHA was present in only 2.9% of African American patients, compared with 6.0% of white patients and 12–25% of patients of other races; this was in striking contrast to the frequency of anti-Sm in African American patients (27.2%). Among patients with SLE, anti-RHA was common in young patients (26% of those whose initial visit was at an age younger than 20 years versus 3–4% of those who were initially seen at ages 20–49 years) and at an early stage of disease (23% of those whose first clinic visit was within 1 year of disease onset versus 2–8% of those whose first visit was at least 1 year after disease onset). In 9 of 11 patients, levels of anti-RHA decreased to |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text